Allianz Asset Management GmbH Buys 53,653 Shares of Organon & Co. $OGN

Allianz Asset Management GmbH raised its stake in Organon & Co. (NYSE:OGN) by 4.2% during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,329,902 shares of the company’s stock after acquiring an additional 53,653 shares during the period. Allianz Asset Management GmbH’s holdings in Organon & Co. were worth $12,873,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Douglas Lane & Associates LLC grew its position in Organon & Co. by 19.0% during the 2nd quarter. Douglas Lane & Associates LLC now owns 315,952 shares of the company’s stock valued at $3,058,000 after purchasing an additional 50,393 shares during the last quarter. Triumph Capital Management lifted its stake in shares of Organon & Co. by 109.1% in the second quarter. Triumph Capital Management now owns 90,342 shares of the company’s stock worth $875,000 after buying an additional 47,127 shares in the last quarter. Sequoia Financial Advisors LLC grew its holdings in shares of Organon & Co. by 42.2% during the first quarter. Sequoia Financial Advisors LLC now owns 19,392 shares of the company’s stock valued at $289,000 after buying an additional 5,758 shares during the last quarter. M&T Bank Corp increased its position in shares of Organon & Co. by 3.4% during the first quarter. M&T Bank Corp now owns 55,990 shares of the company’s stock valued at $833,000 after acquiring an additional 1,854 shares in the last quarter. Finally, WBI Investments LLC bought a new stake in shares of Organon & Co. during the first quarter valued at approximately $946,000. Hedge funds and other institutional investors own 77.43% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d+)” rating on shares of Organon & Co. in a research note on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $17.33.

Organon & Co. Trading Down 0.4%

Shares of OGN stock opened at $9.25 on Tuesday. Organon & Co. has a 12-month low of $8.01 and a 12-month high of $19.05. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 11.98. The firm’s 50 day moving average is $9.94 and its 200 day moving average is $9.97. The stock has a market capitalization of $2.40 billion, a P/E ratio of 3.44, a P/E/G ratio of 0.84 and a beta of 0.63.

Organon & Co. (NYSE:OGN) last announced its earnings results on Tuesday, August 5th. The company reported $1.00 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.06. The business had revenue of $1.59 billion during the quarter, compared to analyst estimates of $1.55 billion. Organon & Co. had a net margin of 11.15% and a return on equity of 163.88%. The company’s quarterly revenue was down .8% compared to the same quarter last year. During the same period in the previous year, the business earned $1.12 EPS. Organon & Co. has set its FY 2025 guidance at EPS. Research analysts expect that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, September 11th. Shareholders of record on Friday, August 15th were given a $0.02 dividend. This represents a $0.08 annualized dividend and a yield of 0.9%. The ex-dividend date of this dividend was Friday, August 15th. Organon & Co.’s dividend payout ratio (DPR) is presently 2.97%.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.